Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatme...Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatment response and future relapse. Patients and methods: Eighty seven newly diagnosed (B-ALL) cases were enrolled in the present study in the time period from October 2013 to October 2016. A panel of 4 monoclonal antibodies (CD10FITC, CD19PE, CD34PercP and CD45APC) were defined at diagnosis and after morphological remission for tracing of minimal residual disease (MRD). Results: Eighty seven newly diagnosed B-ALL cases were included in the present study of which 73 (84%) showed positive expression to CD45 in combination with (CD10, CD19 and CD34) at diagnosis, which allow us to use this combination for further assessment of MRD after morphological remission. In our study 65% of patients had negative MRD ( Conclusion: MRD detection by flow cytometry using the combination of CD45 with CD10, CD19 & CD34 is an easy and reliable method. Patients with positive MRD are at higher risk of relapse and have inferior overall survival rates compared to those with MRD-ve. Future studies focusing on treatment intensification for the group of patients with +ve MRD aiming to improve the treatment outcome are warranted.展开更多
用小剂量 PHA(0.15μg/ml)诱导人 T 细胞从 Go 相进入 G_((?)a)和 G_((?)b)相,但不能进入 S 相和 G_2/M 相,和用人 rIL-2诱导上述活化的 T 细胞进入 S 相和 G_2/M 相作模型,用 AO 和 PI 染色在流式细胞仪上分析了雷公藤总甙 T Ⅱ对 T ...用小剂量 PHA(0.15μg/ml)诱导人 T 细胞从 Go 相进入 G_((?)a)和 G_((?)b)相,但不能进入 S 相和 G_2/M 相,和用人 rIL-2诱导上述活化的 T 细胞进入 S 相和 G_2/M 相作模型,用 AO 和 PI 染色在流式细胞仪上分析了雷公藤总甙 T Ⅱ对 T 细胞增殖反应的影响。结果表明 T Ⅱ在细胞周期 Go→G_(?),G_(?)→G_((?)b),G_(?)→S,和 S→G_2/M 多个关键点上抑制 T 细胞的增殖反应。展开更多
文摘Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatment response and future relapse. Patients and methods: Eighty seven newly diagnosed (B-ALL) cases were enrolled in the present study in the time period from October 2013 to October 2016. A panel of 4 monoclonal antibodies (CD10FITC, CD19PE, CD34PercP and CD45APC) were defined at diagnosis and after morphological remission for tracing of minimal residual disease (MRD). Results: Eighty seven newly diagnosed B-ALL cases were included in the present study of which 73 (84%) showed positive expression to CD45 in combination with (CD10, CD19 and CD34) at diagnosis, which allow us to use this combination for further assessment of MRD after morphological remission. In our study 65% of patients had negative MRD ( Conclusion: MRD detection by flow cytometry using the combination of CD45 with CD10, CD19 & CD34 is an easy and reliable method. Patients with positive MRD are at higher risk of relapse and have inferior overall survival rates compared to those with MRD-ve. Future studies focusing on treatment intensification for the group of patients with +ve MRD aiming to improve the treatment outcome are warranted.
文摘用小剂量 PHA(0.15μg/ml)诱导人 T 细胞从 Go 相进入 G_((?)a)和 G_((?)b)相,但不能进入 S 相和 G_2/M 相,和用人 rIL-2诱导上述活化的 T 细胞进入 S 相和 G_2/M 相作模型,用 AO 和 PI 染色在流式细胞仪上分析了雷公藤总甙 T Ⅱ对 T 细胞增殖反应的影响。结果表明 T Ⅱ在细胞周期 Go→G_(?),G_(?)→G_((?)b),G_(?)→S,和 S→G_2/M 多个关键点上抑制 T 细胞的增殖反应。
